Dr. Michael Schweizer
Claim this profileFred Hutch/University of Washington Cancer Consortium
Expert in Prostate Cancer
Studies Prostate Adenocarcinoma
13 reported clinical trials
26 drugs studied
Area of expertise
1Prostate Cancer
Global LeaderStage IV
HR positive
CDK12 positive
2Prostate Adenocarcinoma
HR positive
CDK12 positive
MSI-H positive
Affiliated Hospitals
Clinical Trials Michael Schweizer is currently running
High-Dose Testosterone + Chemotherapy
for Prostate Cancer
This trial tests if high levels of a hormone combined with cancer treatment can help treat prostate cancer that has spread and is not responding to usual treatments. The hormone may damage cancer cell DNA, and the treatment helps kill or slow the cancer cells.
Recruiting1 award Phase 220 criteria
Vorinostat + 177Lu-PSMA-617
for Metastatic Prostate Cancer
This phase II trial tests how well vorinostat works in treating patients with prostate-specific membrane antigen (PSMA)-low castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) (mCRPC). Prostate cancer that has not spread to other parts of the body (localized) is typically treated through surgery or radiotherapy, which for many men is curable. Despite definitive local therapy, cancer that has come back after a period of improvement (recurrent) disease develops in 27-53% of men. Often this is detected by measurement of prostate-specific antigen (PSA) without visible evidence of metastatic disease. Lutetium Lu 177 vipivotide tetraxetan (177Lu-prostate specific membrane antigen \[PSMA\]-617) is a new small molecule PSMA-targeted radioactive therapy that has been approved by the Food and Drug Administration for the treatment of adult patients with PSMA-positive mCRPC who have been treated with androgen receptor inhibitors and taxane-based chemotherapy. Vorinostat is used to treat various types of cancer that does not get better, gets worse, or comes back during or after treatment with other drugs. Vorinostat is a drug which inhibits the enzyme histone deacetylase and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vorinostat and 177Lu-PSMA-617 may kill more tumor cells in in patients with PSMA-low mCRPC.
Recruiting1 award Phase 215 criteria
More about Michael Schweizer
Clinical Trial Related4 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Michael Schweizer has experience with
- Docetaxel
- Olaparib
- Enzalutamide
- Nivolumab
- Durvalumab
- Abemaciclib
Breakdown of trials Michael Schweizer has run
Prostate Cancer
Prostate Adenocarcinoma
Cancer
- Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
- Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
- CAR T-cell Therapy for Prostate Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Schweizer specialize in?
Michael Schweizer focuses on Prostate Cancer and Prostate Adenocarcinoma. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are HR positive.
Is Michael Schweizer currently recruiting for clinical trials?
Yes, Michael Schweizer is currently recruiting for 5 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Michael Schweizer has studied deeply?
Yes, Michael Schweizer has studied treatments such as Docetaxel, Olaparib, Enzalutamide.
What is the best way to schedule an appointment with Michael Schweizer?
Apply for one of the trials that Michael Schweizer is conducting.
What is the office address of Michael Schweizer?
The office of Michael Schweizer is located at: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington 98109 United States. This is the address for their practice at the Fred Hutch/University of Washington Cancer Consortium.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.